Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells

StatusNot Yet Recruiting
PhasePhase 2/3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Aug 1, 2028 → Dec 31, 2028
See other at-risk trials from The Affiliated People's Hospital of Ningbo University

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: The Affiliated People's Hospital of Ningbo University to The Affiliated People's Hospital of Ningbo University Show 4 more changesShow less
    • Start date: Aug 1, 2026 to Jan 1, 2027
    • Primary completion pushed from Aug 1, 2028 to Dec 31, 2028
    • Study completion pushed from Dec 1, 2028 to Dec 31, 2030
    • Eligibility criteria expanded, about 14 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
To evaluate the overall response rate, safety, and the 12-cycle clearance rate of circulating plasma cells (CPCs) in patients with newly diagnosed transplant-ineligible multiple myeloma stratified as high-risk based on circulating plasma cell assessment treated with isatuximab combined with reduced-dose VRD regimen
Trial Details
NCT Number NCT07732712
Lead Sponsor The Affiliated People's Hospital of Ningbo University
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov